Acetyl-L-carnitine

Phase 3Small molecule

Mario Negri Institute for Pharmacological Research

Acetyl-L-carnitine is one of 123 small molecule programs targeting Osteoarthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

122

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoarthritisActive, not recruiting

EncephalopathyActive, not recruiting

AtaxiaActive, not recruiting

TrialRecruiting

OsteoarthritisPreclinical

Active, not recruiting

EncephalopathyPreclinical

Active, not recruiting

AtaxiaPreclinical

Active, not recruiting

TrialPhase 3

Recruiting

Competition

Competitive Landscape

143 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Acetyl-L-carnitine

Mario Negri Institute for Pharmacological Research

Phase 3

1 2

Toradol

Roche

Preclinical

1 3

Cataflam

Bayer Aspirin

Enbrel

2 6

Glucophage

EMD Serono

Preclinical

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 8

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2/3Recruiting

Trial

NCT06126315

Clinical

Trials by Indication[1]

Encephalopathy3 trials

Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy

Completed·UUniversity of Catania·N/A·NCT01223729·67 enrolled

Acetyl-L-Carnitine In Severe Hepatic Encephalopathy

Completed·UUniversity of Catania·N/A·NCT01223768

Acetyl-L-Carnitine Reduces Perceived Work Stress and Improves Work Ability and Work Performance in Hepatic Encephalopathy

Completed·UUniversity of Catania·Phase 3·NCT02173132·94 enrolled

Peripheral Neuropathy2 trials

Preventive Effect of Acetyl-L-carnitine on Oxaliplatin-induced Peripheral Neuropathy

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2·NCT05601479·100 enrolled

Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00050271·27 enrolled

Carpal Tunnel Syndrome1 trial

Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome

Completed·UUniversity of Alberta·Phase 2/3·NCT02141035·20 enrolled

Ataxia1 trial

An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia

Unknown status·UUniversity of South Florida·N/A·NCT01921868·20 enrolled

CAR1 trial

Acetyl-L-Carnitine Supplementation During HCV Therapy With Peg IFN-α2b Plus Ribavirin: Effect on Work Performance.

Completed·UUniversity of Catania·Phase 3·NCT01909557·62 enrolled

6 more indications

Alzheimer's Disease1 trial

Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease

Completed·DDong-A ST Co., Ltd.·Phase 4·NCT02955706·265 enrolled

Prophylaxis1 trial

ALCAR Prophylaxis Study

Unknown status·RRoyal Free Hampstead NHS Trust·Phase 2·NCT00225160·50 enrolled

Trial1 trial

Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS

Recruiting· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2/3·NCT06126315·246 enrolled

Septic Shock1 trial

Acetyl-L-Carnitine in the Treatment of Septic Shock

Completed·VVanderbilt University·Phase 1/2·NCT00592488·13 enrolled

Migraine1 trial

Effect of Acetyl-L-carnitine in Migraine

Completed·NNorwegian University of Science and Technology·Phase 4·NCT01695317·72 enrolled

Osteoarthritis1 trial

Effects of Acetyl L-Carnitine Supplementation on Clinical, Metabolic and Inflammatory Symptoms in Obese, Diabetic, Postmenopausal Women With Osteoarthritis: Randomized Controlled Trial

Completed·KKhyber Medical University Peshawar·Preclinical·NCT07660081·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Acetyl-L-carnitine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Acetyl-L-carnitine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Acetyl-L-carnitine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mario Negri Institute for Pharmacological Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Mario Negri Institute for Pharmacological Research

Acetyl-L-carnitine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Encephalopathy3 trials

Peripheral Neuropathy2 trials

Carpal Tunnel Syndrome1 trial

Ataxia1 trial

CAR1 trial

Alzheimer's Disease1 trial

Prophylaxis1 trial

Trial1 trial

Septic Shock1 trial

Migraine1 trial

Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News